Search

everythinglearnresearchcommunity

for

Search:↓

Dutasteride reduces DHT more effectively than finasteride.

Combination therapies work better than single treatments for hair loss.

Taking 5-Alpha Reductase Inhibitors before bladder removal surgery might make high-grade bladder tumors less aggressive.

Dutasteride reduces hospitalization and prostate cancer risk compared to finasteride, potentially offsetting its higher cost.

Seminal bacteria can lower sperm quality in subfertile men.

Finasteride for hair loss lowers PSA levels, so PSA values need adjusting when screening for prostate cancer.

Dutasteride is a safe and effective treatment for hair loss.

Finasteride and dutasteride effectively reduce DHT in hair, which may help evaluate their treatment success for hair loss.

Older patients sticking to their prostate medication saw lasting health benefits.

5-alpha-reductase inhibitors lower PSA density but higher PSA density indicates disease progression.

Canadian lawsuits involving 5-alpha-reductase inhibitors are related to persistent erectile dysfunction side effects, with no judgments against companies yet.

BPH medications may increase the risk of self-harm and depression, especially in the first 18 months.

Anti-androgen therapy might help protect against COVID-19 infection and reduce death risk.

Finasteride and dutasteride do not significantly change beard thickness in men.

Odds Ratios can be misleading; it's better to also present risk and Relative Risks for clarity.

Most legal cases about 5α-reductase inhibitors, drugs for hair loss and prostate issues, complain about side effects and delayed cancer diagnosis, with most lawsuits settled out of court.

The authors suggest that 5-α-reductase inhibitors, like dutasteride, are effective in treating frontal fibrosing alopecia and should be the first-line treatment, with other options for severe cases. They also recommend further research on Janus kinase inhibitors.

Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might reduce it. AST decreases recurrence-free survival but doesn't affect overall survival or progression-free survival. More research is needed to understand AST's benefits.

Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might decrease the risk. AST also lessens the chance of cancer coming back but doesn't really affect survival rates. More research is needed to understand AST's benefits for different bladder cancers.

Finasteride, a drug that prevents testosterone conversion, can effectively reduce blood loss in prostate surgery, especially for patients with a prostatic volume over 30 cc, and decrease post-surgery complications.

5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.

5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.

Using 5-alpha-reductase inhibitors, drugs for prostate issues and hair loss, may lead to eye abnormalities in men.

5-alpha reductase inhibitors may reduce bladder cancer recurrence and improve survival.

5-alpha-reductase inhibitors might help slow down low-risk prostate cancer, but their use should be cautious.